Home: Oncology Leader Commentary: C Kent Osbourne, MD

Click on the topic below for comments by Dr C Kent Osborne to comment on. You will also find links to related articles and clinical trials.

Problems with estrogen receptor assays
Cut-off for ER-positivity
Receptor assays in metastatic disease
Mechanism of action of Faslodex
Receptor downregulation and Faslodex
Faslodex effects in the laboratory
Randomized trials comparing Faslodex to Arimidex
Tolerability of Faslodex
Other trials of Faslodex
Future Clinical role of Faslodex
Intramuscular injection of Faslodex
Clinical trials of adjuvant Faslodex
Management of DCIS
Future trials of Faslodex plus estrogen

Future trials of Faslodex plus estrogen

Interview with Neil Love, MD Breast Cancer Update for Medical Oncologists, Program 6 2000

Play Audio Below:

If it is true that in humans Faslodex doesn’t cross the blood-brain-barrier and if, in fact, the central nervous system is where menopausal symptoms originate – mental status alternations, hot flashes – and there’s pretty good evidence that it does, then you can imagine a situation that for prevention, if Faslodex was a really great drug to block proliferation of normal ductal epithelium and atypical hyperplasias, that a combined use of low doses of Premarin plus Faslodex would at least help that problem. Now, you might have an issue with bones in that circumstance. But there are other drugs that work on bones. I’m sure that we’ll have, eventually, a Fosamax that is tolerated by a larger percentage of patients. Right now, I don’t know, maybe 25 or 30 percent, in my own experience, seems like have difficulty tolerating Fosamax. The others don’t. But we’ll have better bisphosphonates and better bone-sparing agents. So, I wouldn’t totally rule out drugs like Faslodex for prevention.

Relevant Articles:

Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?
Zand, R. S. R.; Grass, L.; Magklara, A.; Jenkins, D. J. A., and Diamandis, E. P. (Reprint available from: Zand RSR Mt Sinai Hosp, Dept Pathol & Lab Med 600 Univ Ave Toronto ON M5G 1X5 Canada). Breast Cancer Research & Treatment. 60(1):1-8, 2000 Mar.

Selective estrogen receptor modulators: Structure, function, and clinical use [Review].
Osborne, C. K. and Fuqua, S. A. W. Journal of Clinical Oncology. 18(17):3172-3186, 2000 Sep.

Development of a novel, "pure" antiestrogen.
Howell, A.; Osborne, C. K.; Morris, C., and Wakeling, A. E. ICI 182,780 (Faslodex (TM)) -. Cancer. 89(4):817-825, 2000 Aug 15.

Similarities and distinctions in the mode of action of different classes of antioestrogens [Review].
Wakeling, A. E. Endocrine-Related Cancer. 7(1):17-28, 2000 Mar. No abstract

Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: A brief overview.
Terakawa, N. (Reprint available from: Terakawa N Tottori Univ, Sch Med, Dept Obstet & Gynecol Yonago Tottori 683 Japan).. Oncology. 59(Suppl 1):3-4, 2000. No abstract

Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells.
Smolnikar, K.; Loffek, S.; Schulz, T.; Michna, H., and Diel, P. (Reprint available from: Smolnikar K DSHS Cologne, Inst Morphol & Tumor Res Carl Diem Weg 6 D-50927 Cologne Germany). Breast Cancer Research & Treatment. 63(3):249-259, 2000 Oct. In process

Symposium overview: Estrogens and antiestrogens in managing the patient with breast cancer.
Newman, L. A.; Wood, W. C.; Sellin, R. V.; Morrow, M.; Vogel, C., and Singletary, S. E (Reprint available from: Singletary SE Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol 1515 Holcombe Blvd,Box 106 Houston, TX 77030 USA).. Annals of Surgical Oncology. 7(8):568-574, 2000 Sep. In process

Top of Page